Jill Wechsler

Jill Wechsler is Pharm Exec's Washington Corespondent


Biotech Execs Pledge “Reasonable” Price Increases

January 13, 2020

More than 200 biopharma leaders acknowledge that out-of-pocket costs for individuals must be limited to sustain support for fiscal and patent policies key to advancing innovation.

New Drug Approvals Stay Strong in 2019

January 03, 2020

While not setting any records for the rapid approval of new drugs in 2019, FDA did speed a number of important new therapies to patients, writes Jill Wechsler.

Hahn Confirmed as FDA Commissioner

December 12, 2019

FDA has an official new leader, following a Senate vote to confirm Stephen Hahn as the agency’s next commissioner.

New FDA Model Aims to Speed More Rare Disease Treatments to Patients

October 29, 2019

CDER's Rare Disease Cures Accelerator initiative looks to foster a coordinated research approach and methods that can expedite development of drugs to treat some of the 7,000 rare diseases.

FDA Moves to Modernize Drug Review Process

April 11, 2019

A new CDER “knowledge management” approach will see companies submit applications that can be transmitted to experts from multiple disciplines able to assess applications for new drugs and biologics in a timely and efficient manner.

FDA Moves to Overhaul New Drug Review Process

May 07, 2018

FDA officials make efforts to better manage the increasing amount of applications for new drugs that treat disease in innovative ways and include new kinds of clinical research, starting with a plan to restructure the Office of New Drugs (OND) in the Center for Drug Evaluation and Research (CDER).